KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EBIT (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed EBIT for 8 consecutive years, with -$12.8 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 62.25% to -$12.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$57.1 million through Dec 2025, up 64.86% year-over-year, with the annual reading at -$57.1 million for FY2025, 64.86% up from the prior year.
  • EBIT hit -$12.8 million in Q4 2025 for Adaptive Biotechnologies, down from $10.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $10.3 million in Q3 2025 to a low of -$71.1 million in Q4 2023.
  • Historically, EBIT has averaged -$42.8 million across 5 years, with a median of -$47.6 million in 2023.
  • Biggest five-year swings in EBIT: crashed 81.36% in 2023 and later surged 131.53% in 2025.
  • Year by year, EBIT stood at -$61.6 million in 2021, then skyrocketed by 36.38% to -$39.2 million in 2022, then plummeted by 81.36% to -$71.1 million in 2023, then skyrocketed by 52.39% to -$33.8 million in 2024, then skyrocketed by 62.25% to -$12.8 million in 2025.
  • Business Quant data shows EBIT for ADPT at -$12.8 million in Q4 2025, $10.3 million in Q3 2025, and -$25.0 million in Q2 2025.